Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture
B A Chabner1, A L Boral, P Multani
1Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Abstract:
Advances in the understanding of normal and malignant cell biology are allowing the development of biologically targeted drugs directed at specific differences between host and tumor. The array of potential new targets is vast, but drugs currently in development are targeted at cell-cycle regulators, growth factors and their receptors, signal transduction intermediates, angiogenesis, and the mechanisms that mediate apoptosis and DNA repair. Recent results raise the possibility that novel biologically targeted agents, perhaps in combination with traditional cytotoxic agents, may finally cure cancer. However, the development of a biologically targeted drug raises unique challenges in the design of clinical trials to demonstrate its efficacy, and despite the promising preclinical data that exist for most of the agents in development, the clinical trial remains the critical, final step across the bridge from basic research to clinical application. In this review, we discuss some of the challenges in the clinical development of biologically targeted agents and the implications for clinical trial design.
Insights
Biologically targeted cancer drugs show promise for cures by targeting specific cell differences. However, clinical trial design challenges remain critical for demonstrating efficacy from research to patient application.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Advances in understanding cancer cell biology enable the development of targeted therapies.
- Current research focuses on targets like cell-cycle regulators, growth factors, and apoptosis mechanisms.
Discussion:
- Biologically targeted agents offer potential cancer cures, possibly combined with traditional chemotherapy.
- Unique challenges exist in designing clinical trials for these novel agents.
- Preclinical data is promising, but clinical trials are essential for validating efficacy.
Key Insights:
- Targeted therapies exploit specific differences between normal and malignant cells.
- Developing targeted drugs requires overcoming significant clinical trial design hurdles.
- Successful clinical translation hinges on rigorous trial evaluation.
Outlook:
- Novel targeted agents may revolutionize cancer treatment.
- Optimizing clinical trial design is crucial for realizing the full potential of targeted therapies.
- The integration of targeted agents with existing treatments warrants further investigation.
